The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

Studies designed, executed and funded by Alkermes, Inc.

Filter Publications
Therapeutic Area:
Publication Type:
Showing 10 of 99 results
Sort by date: Descending
Sep 2022
Olanzapine/samidorphan mitigates weight gain across subgroups of patients known to be at increased risk for weight gain with olanzapine treatment
CNS Spectrums
AUTHOR(S)

Jonathan M Meyer, Adam Simmons, Ying Jiang, Christine Graham, Sergey Yagoda, David McDonnell

View on PubMed
Clinical
Schizophrenia
May 2022
Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals
CNS Spectrums
AUTHOR(S)
Sommi RW, Rege B, Wehr A, Faldu S, Du Y, Weiden PJ
View on PubMed
Review/Commentary
Schizophrenia
Mar 2022
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials
Drug and Alcohol Dependence
AUTHOR(S)
Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A
View on PubMed
Clinical
Opioid Use Disorder
Mar 2022
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting
The American Journal on Addictions
AUTHOR(S)
Mannelli P, Douaihy AB, Akerman SC, Legedza A, Fratantonio J, Zavod A, Sullivan MA
View on PubMed
Clinical
Opioid Use Disorder
Feb 2022
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
Neuropsychopharmacology
AUTHOR(S)

Toledo FGS, Martin WF, Morrow L, Beysen C, Bajorunas D, Jiang Y, Silverman BL, McDonnell D, Namchuk MN, Newcomer JW, Graham C

View on PubMed
Clinical
General
Jan 2022
Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study
Schizophrenia Bulletin Open
AUTHOR(S)

Caligiuri MP, Weiden PJ, Legedza A, Yagoda S, Claxton A

View on PubMed
Clinical
Schizophrenia
Nov 2021
Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone
The American Journal of Drug and Alcohol Abuse
AUTHOR(S)
Mannelli P, Douaihy AB, Zavod A, Legedza A, Akerman SC, Sullivan MA
View on PubMed
Clinical
Opioid Use Disorder
Sep 2021
Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.
BMC Psychiatry
AUTHOR(S)
Nasrallah HA, Weiden PJ, Walling DP, Du Y, Yao B, Yagoda S, Claxton A
View on PubMed
Clinical
Schizophrenia
Sep 2021
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
CNS Drugs
AUTHOR(S)
Lauriello J, Weiden PJ, Gleeson CD, Shah A, Boulanger L, Jariwala-Parikh K, Hedgeman E, O'Sullivan AK
View on PubMed
Real World Evidence
Schizophrenia
Aug 2021
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Neuropsychiatric Disease and Treatment
AUTHOR(S)

Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D

View on PubMed
Review/Commentary
Bipolar Disorder
Schizophrenia